Fact CheckerSign in

NCT03676647Recruiting

Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

Retrospective-Prospective Collection of Thyroid Specimens After FNA

Source: ClinicalTrials.gov · Last updated 2 Jun 2026

Brief summary (registry, in English)

This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, such as the diagnostic DNA methylation signature, may be a less invasive way to check for thyroid cancer.

Status (registry)
Recruiting
Study type
Observational
Enrollment
22 (estimated)
First submitted
17 Sept 2018
Start date
1 Jan 2027
Primary completion date
25 Sept 2028
Lead sponsor
City of Hope Medical Center
NCT number
NCT03676647

What you commit to

  • Study type: Observational
  • Planned participants: 22
  • From 1 Jan 2027 to the primary completion date, 25 Sept 2028
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

  • All patients undergoing FNA for thyroid nodule diagnosis.
  • Any race and ethnicity are eligible for the study.
  • Patient should have thyroid nodule(s) with indeterminate diagnosis after FNA (Bethesda category of indeterminate FNA \[III-V\]).

Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
City of Hope Medical Center
Coordinator of this site? Confirm its status
DuarteUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.